CARM: AI 评分 61/100 — AI 分析 (4月 2026)

Carisma Therapeutics, Inc. is a biopharmaceutical company focused on developing CAR-macrophage therapies for solid tumors. Their innovative approach leverages the innate and adaptive immune systems to fight cancer.

Key Facts: Price: $0.04 AI Score: 61/100 Sector: Healthcare

公司概况

概要：

Carisma Therapeutics pioneers CAR-macrophage therapies, harnessing the power of innate and adaptive immunity to revolutionize solid tumor treatment, offering a novel approach in the biopharmaceutical landscape and a strategic collaboration with Moderna.

CARM是做什么的？

Carisma Therapeutics, Inc., founded in 2016 and based in Philadelphia, Pennsylvania, is a biopharmaceutical company at the forefront of developing chimeric antigen receptor (CAR) macrophages as a novel approach to treating solid tumors. Recognizing the crucial role macrophages play in both the innate and adaptive immune responses, Carisma has engineered a technology platform that leverages advances in macrophage biology, CAR engineering, and adoptive cellular therapy. This innovative approach aims to overcome the limitations of traditional cancer treatments by harnessing the body's own immune system to target and destroy tumor cells. Carisma's evolution from CARMA Therapeutics Inc. in 2017 reflects its focused commitment to this specialized area of immunotherapy. The company's strategic collaboration with Moderna Inc. further validates its technology and provides significant resources for research and development. Carisma's core focus is on creating off-the-shelf CAR-macrophage therapies that can be readily administered to patients, offering a potentially more effective and accessible treatment option for a wide range of solid tumors. The company's pioneering work positions it as a key player in the next generation of cancer immunotherapies.

CARM的投资论点是什么？

Carisma Therapeutics presents a notable market position due to its innovative CAR-macrophage platform targeting solid tumors, an area with significant unmet medical need. The strategic collaboration with Moderna provides validation and financial resources, de-risking the investment to some extent. With a gross margin of 98.1%, the company demonstrates potential for high profitability upon commercialization. Key value drivers include successful clinical trial outcomes and potential FDA approval of its lead candidates. Upcoming clinical data releases in 2026 and beyond could serve as major catalysts. The company's focus on off-the-shelf therapies addresses accessibility challenges, further enhancing its market potential. the may be worth researching high beta of 3.70, indicating significant volatility, and closely monitor clinical trial progress and regulatory milestones.

CARM在哪个行业运营？

Carisma Therapeutics operates within the rapidly evolving biotechnology industry, specifically in the cancer immunotherapy segment. The CAR-T cell therapy market is experiencing significant growth, with projections estimating a market size of billions of dollars by 2030. Carisma's CAR-macrophage approach represents a novel alternative to CAR-T cells, potentially offering advantages in terms of safety and efficacy, particularly in solid tumors. The competitive landscape includes companies like ASBP, CDT, ENVB, INDP, and JSPR, which are developing various cancer therapies. Carisma's strategic collaboration with Moderna positions it favorably in this competitive environment, providing access to resources and expertise.

Biotechnology

Healthcare

CARM有哪些增长机遇？

Expansion of CAR-Macrophage Pipeline: Carisma has the opportunity to expand its pipeline of CAR-macrophage therapies to target a broader range of solid tumors. This includes exploring new CAR designs and target antigens to address different cancer types. The market for targeted cancer therapies is substantial, with estimates reaching tens of billions of dollars annually. Successful development and clinical validation of new CAR-macrophage candidates could significantly increase Carisma's market share and revenue potential. Timeline: Ongoing, with new programs expected to enter preclinical development within the next 1-2 years.
Advancement of Lead Candidate Through Clinical Trials: Carisma's lead CAR-macrophage candidate is currently in clinical trials. Positive clinical data and successful advancement through regulatory milestones, including potential FDA approval, represent a major growth opportunity. The market for effective solid tumor therapies is immense, with a significant unmet need for novel treatments. Successful commercialization of the lead candidate could generate substantial revenue and establish Carisma as a leader in the CAR-macrophage field. Timeline: Ongoing, with key clinical data readouts expected in the next 12-18 months.
Strategic Partnerships and Collaborations: Carisma can pursue additional strategic partnerships and collaborations with other pharmaceutical and biotechnology companies to accelerate the development and commercialization of its CAR-macrophage therapies. These partnerships could provide access to additional funding, expertise, and resources. The market for collaborative drug development is robust, with numerous opportunities for companies to leverage each other's strengths. Successful partnerships could significantly enhance Carisma's growth prospects. Timeline: Ongoing, with potential for new partnerships to be established within the next 1-2 years.
Expansion into New Geographic Markets: Carisma has the opportunity to expand its operations into new geographic markets, particularly in Europe and Asia, where there is a growing demand for innovative cancer therapies. This expansion could involve establishing new research and development facilities, partnering with local distributors, or directly commercializing its products in these markets. The global market for cancer therapies is substantial, with significant growth potential in emerging markets. Timeline: Medium-term, with potential for expansion into new markets within the next 3-5 years.
Development of Off-the-Shelf CAR-Macrophage Therapies: Carisma's focus on developing off-the-shelf CAR-macrophage therapies provides a significant competitive advantage. These therapies can be readily administered to patients without the need for personalized manufacturing, making them more accessible and cost-effective. The market for off-the-shelf cell therapies is growing rapidly, driven by the increasing demand for convenient and affordable treatments. Successful development and commercialization of off-the-shelf CAR-macrophage therapies could significantly increase Carisma's market share. Timeline: Ongoing, with continued focus on optimizing manufacturing processes and scalability.

Strategic collaboration with Moderna Inc. validates Carisma's technology and provides financial support.
Gross margin of 98.1% indicates strong potential profitability upon commercialization.
Focus on CAR-macrophage therapies offers a novel approach to treating solid tumors, addressing a significant unmet need.
The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
P/E ratio of 0.22 suggests the company is potentially undervalued relative to its earnings.

CARM提供哪些产品和服务？

Develops chimeric antigen receptor (CAR) macrophages.
Creates therapies for the treatment of solid tumors.
Leverages macrophage biology for immune response.
Utilizes chimeric antigen receptor engineering.
Applies adoptive cellular therapy.
Focuses on innate and adaptive immune response.

CARM如何赚钱？

Develops and patents CAR-macrophage technology.
Outlicenses or co-develops therapies with partners like Moderna.
Generates revenue through milestone payments and royalties.
Conducts clinical trials to validate efficacy and safety.

Patients with solid tumors.
Hospitals and oncology clinics.
Pharmaceutical companies through partnerships.
Research institutions for collaborative studies.

Proprietary CAR-macrophage technology platform.
Strategic collaboration with Moderna Inc.
Expertise in macrophage biology and CAR engineering.
Focus on off-the-shelf therapies for accessibility.

什么因素可能推动CARM股价上涨？

Upcoming: Clinical data releases from ongoing Phase 1/2 trials in 2026.
Upcoming: Potential initiation of Phase 3 trials in 2027 pending Phase 2 results.
Ongoing: Expansion of CAR-macrophage pipeline to new solid tumor targets.
Ongoing: Continued progress in strategic collaboration with Moderna.

CARM的主要风险是什么？

Potential: Clinical trial failures or delays.
Potential: Regulatory setbacks or non-approval.
Potential: Competition from established pharmaceutical companies.
Ongoing: High cash burn rate and potential need for future financing.
Ongoing: Dependence on the success of the Moderna collaboration.

CARM的核心优势是什么？

Innovative CAR-macrophage technology.
Strategic partnership with Moderna.
High gross margin potential.
Experienced management team.

CARM的劣势是什么？

Early-stage clinical development.
Limited financial resources.
High dependence on Moderna collaboration.
Small number of employees.

CARM有哪些机遇？

Expansion of pipeline to new tumor targets.
Positive clinical trial results.
Additional strategic partnerships.
FDA approval and commercialization.

CARM面临哪些威胁？

Clinical trial failures.
Regulatory hurdles.
Competition from established players.
Dilution from future fundraising.

CARM的竞争对手是谁？

Ascent Bio-Pharmaceuticals, Inc. — Focuses on generic and specialty pharmaceuticals. — (ASBP)
Codiak BioSciences, Inc. — Develops exosome-based therapeutics. — (CDT)
Enveric Biosciences, Inc. — Focuses on cannabinoid medicines for cancer. — (ENVB)
Indaptus Therapeutics, Inc. — Developing targeted immunotherapies. — (INDP)
Jasper Therapeutics, Inc. — Developing engineered hematopoietic cell therapies. — (JSPR)

Key Metrics

Price: $0.04 (+4.26%)
Market Cap: $2.0M
P/E Ratio: 0.20
MoonshotScore: 61/100

常见问题

What does Carisma Therapeutics, Inc. (CARM) do?

Carisma Therapeutics, Inc. is a biopharmaceutical company pioneering a novel approach to cancer treatment by developing chimeric antigen receptor (CAR) macrophages. These engineered macrophages are designed to harness the power of the innate and adaptive immune systems to target and destroy solid tumors. Carisma's technology leverages advances in macrophage biology, CAR engineering, and adoptive cellular therapy, offering a potentially more effective and accessible treatment option for a wide range of cancers. The company's strategic collaboration with Moderna further strengthens its position in the field.

Is CARM stock a good buy?

Evaluating whether CARM stock is a good buy requires careful consideration. The company's innovative CAR-macrophage technology and strategic partnership with Moderna present significant growth potential. However, as a clinical-stage biopharmaceutical company, CARM carries inherent risks associated with drug development, including clinical trial failures and regulatory hurdles. While the P/E ratio of 0.22 might suggest undervaluation, investors should weigh this against the company's high beta of 3.70, indicating significant volatility. A comprehensive assessment of CARM's clinical trial progress and financial stability is crucial before making an investment decision.

What are the risks of investing in CARM?

Investing in Carisma Therapeutics (CARM) carries several risks inherent to the biotechnology industry. A primary risk is the potential for clinical trial failures or delays, which could significantly impact the company's valuation and future prospects. Regulatory hurdles and the possibility of non-approval by the FDA also pose substantial risks. Furthermore, CARM faces competition from larger, more established pharmaceutical companies with greater resources. The company's high cash burn rate and potential need for future financing could lead to dilution of existing shareholders. Dependence on the success of the Moderna collaboration also represents a significant risk factor.

What catalysts could move CARM stock?

Several catalysts could potentially move CARM stock in the near to medium term. Upcoming clinical data releases from ongoing Phase 1/2 trials will be closely watched by investors, with positive results likely to drive the stock price higher. The potential initiation of Phase 3 trials, contingent on the success of Phase 2, would also serve as a significant catalyst. Furthermore, any expansion of the CAR-macrophage pipeline to new solid tumor targets or positive developments in the strategic collaboration with Moderna could positively impact investor sentiment and stock performance.

What is CARM stock price target?

As of March 3, 2026, there is no readily available analyst consensus price target for CARM stock. This may be due to the company's relatively small market capitalization and early stage of development. Investors should conduct their own due diligence and consider factors such as the company's clinical trial progress, financial position, and industry trends to determine a fair value estimate for CARM stock. Monitoring future analyst reports and price target updates will be crucial for gauging market sentiment and potential upside.